Asia
Immuno-oncology has become a key lynchpin in the pipelines of many pharmaceutical companies. The global cancer immunotherapy market is expected to more than double over the next eight years to $126.9 billion by 2026.
TLC announced the upcoming presentation of two scientific abstracts on TLC590 which have been accepted for the 44th Annual Regional Anesthesiology & Acute Pain Medicine Meeting hosted by the American Society of Regional Anesthesia and Pain Medicine.
Winners of Ibtikari program present innovative startups at Angel Rising Investor Education Symposium
The four winners of the Khalifa Fund for Enterprise Development and startAD’s Ibtikari (My Innovation) program, which aims to inspire Emiratis to come up with innovative ideas across various fields, recently presented their projects during Ibtikari Demo Day held in conjunction with Angel Rising Investor Education Symposium at New York University Abu Dhabi.
The Principals MENA (TPM), a fast-growing brand marketing company in the Middle East and North Africa (MENA), recently launched its latest range of best-in-class health, skin and hair care products from a network of leading international partners, at a special launching event held at V Hotel, The Palm.
A U.S. Food and Drug Administration (FDA) advisory panel voted 14 to 0 against recommending Neuronix’s NeuroAD system for the treatment of mild to moderate Alzheimer’s disease.
The widespread global outreach potential of stem cell therapies is becoming apparent, especially given the recent news of a second person going into long-term remission (some saying “cured”) of HIV after undergoing a stem cell transplant.
The debacle raised three broad questions: What will Biogen do next? Is the amyloid theory of Alzheimer’s now dead? And what else is going on in the Alzheimer’s drug development arena?
Biotech and pharma companies make appointments to strengthen executive teams, with moves at Sanofi, Forma, Orchard, CLSA, Sangamo, and more.
The United Food and Commercial Workers Local 1500 (UFCW Local 1500) filed a class action lawsuit against AbbVie for allegedly using a group of patents to maintain a monopoly on its blockbuster Humira (adalimumab).
Perhaps the last big hope for a successful Alzheimer’s drug just died. Biogen and its collaboration partner, Eisai, announced they were discontinuing the global Phase III clinical trials of aducanumab in patients with mild cognitive impairment from Alzheimer’s.
PRESS RELEASES